Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 155

1.

[Corrigendum] Cisplatin in combination with zoledronic acid: A synergistic effect in triple-negative breast cancer cell lines.

Ibrahim T, Liverani C, Mercatali L, Sacanna E, Zanoni M, Fabbri F, Zoli W, Amadori D.

Int J Oncol. 2016 Sep;49(3):1260. doi: 10.3892/ijo.2016.3613. Epub 2016 Jul 6.

2.

CYP17A1 polymorphisms and clinical outcome of castration-resistant prostate cancer patients treated with abiraterone.

Salvi S, Casadio V, Burgio SL, Conteduca V, Rossi L, Menna C, Carretta E, Costantini M, Zoli W, De Giorgi U.

Int J Biol Markers. 2016 Jul 30;31(3):e264-9. doi: 10.5301/jbm.5000197.

PMID:
26954071
3.

Urine Cell-Free DNA Integrity Analysis for Early Detection of Prostate Cancer Patients.

Salvi S, Gurioli G, Martignano F, Foca F, Gunelli R, Cicchetti G, De Giorgi U, Zoli W, Calistri D, Casadio V.

Dis Markers. 2015;2015:574120. doi: 10.1155/2015/574120. Epub 2015 Aug 27.

4.

eNOS polymorphisms as predictors of efficacy of bevacizumab-based chemotherapy in metastatic colorectal cancer: data from a randomized clinical trial.

Ulivi P, Scarpi E, Passardi A, Marisi G, Calistri D, Zoli W, Del Re M, Frassineti GL, Tassinari D, Tamberi S, Vertogen B, Amadori D.

J Transl Med. 2015 Aug 11;13:258. doi: 10.1186/s12967-015-0619-5.

5.

IL-17/IL-10 double-producing T cells: new link between infections, immunosuppression and acute myeloid leukemia.

Musuraca G, De Matteis S, Napolitano R, Papayannidis C, Guadagnuolo V, Fabbri F, Cangini D, Ceccolini M, Giannini MB, Lucchesi A, Ronconi S, Mariotti P, Savini P, Tani M, Fattori PP, Guidoboni M, Martinelli G, Zoli W, Amadori D, Carloni S.

J Transl Med. 2015 Jul 15;13:229. doi: 10.1186/s12967-015-0590-1.

6.

ALK translocation detection in non-small cell lung cancer cytological samples obtained by TBNA or EBUS-TBNA.

Bravaccini S, Tumedei MM, Ulivi P, Zoli W, Calistri D, Candoli P, Amadori D, Puccetti M.

Cytopathology. 2016 Apr;27(2):103-7. doi: 10.1111/cyt.12237. Epub 2015 Mar 10.

PMID:
25757141
7.

EGFR methylation and outcome of patients with advanced colorectal cancer treated with cetuximab.

Chiadini E, Scarpi E, Passardi A, Calistri D, Valgiusti M, Saragoni L, Zoli W, Amadori D, Ulivi P.

Oncol Lett. 2015 Mar;9(3):1432-1438. Epub 2015 Jan 14.

8.

Circulating tumor cells and epithelial, mesenchymal and stemness markers: characterization of cell subpopulations.

Barriere G, Fici P, Gallerani G, Fabbri F, Zoli W, Rigaud M.

Ann Transl Med. 2014 Nov;2(11):109. doi: 10.3978/j.issn.2305-5839.2014.10.04. Review.

9.

Albumin nanocapsules containing fenretinide: pre-clinical evaluation of cytotoxic activity in experimental models of human non-small cell lung cancer.

Pignatta S, Orienti I, Falconi M, Teti G, Arienti C, Medri L, Zanoni M, Carloni S, Zoli W, Amadori D, Tesei A.

Nanomedicine. 2015 Feb;11(2):263-73. doi: 10.1016/j.nano.2014.10.004. Epub 2014 Nov 18.

PMID:
25461293
10.

Improving reliability of live/dead cell counting through automated image mosaicing.

Piccinini F, Tesei A, Paganelli G, Zoli W, Bevilacqua A.

Comput Methods Programs Biomed. 2014 Dec;117(3):448-63. doi: 10.1016/j.cmpb.2014.09.004. Epub 2014 Sep 28.

PMID:
25438936
11.

New biomarkers to predict the evolution of in situ breast cancers.

Bravaccini S, Tumedei MM, Scarpi E, Zoli W, Rengucci C, Serra L, Curcio A, Buggi F, Folli S, Rocca A, Maltoni R, Puccetti M, Amadori D, Silvestrini R.

Biomed Res Int. 2014;2014:159765. doi: 10.1155/2014/159765. Epub 2014 Aug 26.

12.

Improved stool DNA integrity method for early colorectal cancer diagnosis.

Rengucci C, De Maio G, Menghi M, Scarpi E, Guglielmo S, Fusaroli P, Caletti G, Saragoni L, Casadei Gardini A, Zoli W, Falcini F, Amadori D, Calistri D.

Cancer Epidemiol Biomarkers Prev. 2014 Nov;23(11):2553-60. doi: 10.1158/1055-9965.EPI-14-0379. Epub 2014 Aug 15.

13.

Role of BRAF molecular analysis in the management of papillary thyroid carcinoma: analysis of cytological and histological samples.

Capelli L, Marfisi C, Puccetti M, Saragoni L, De Paola F, Zaccaroni A, Chiadini E, Gagliardi L, Ferretti G, Zoli W, Ulivi P.

Cytopathology. 2015 Oct;26(5):297-302. doi: 10.1111/cyt.12199. Epub 2014 Aug 14.

PMID:
25123949
14.

Promoter methylation of tumor suppressor genes in pre-neoplastic lesions; potential marker of disease recurrence.

Rengucci C, De Maio G, Casadei Gardini A, Zucca M, Scarpi E, Zingaretti C, Foschi G, Tumedei MM, Molinari C, Saragoni L, Puccetti M, Amadori D, Zoli W, Calistri D.

J Exp Clin Cancer Res. 2014 Aug 5;33:65. doi: 10.1186/s13046-014-0065-x.

15.

Discrepancies between VEGF -1154 G>A polymorphism analysis performed in peripheral blood samples and FFPE tissue.

Marisi G, Passardi A, Calistri D, Zoli W, Amadori D, Ulivi P.

Int J Mol Sci. 2014 Jul 30;15(8):13333-43. doi: 10.3390/ijms150813333.

16.

Long-term complete response in a patient with liver metastases from breast cancer treated with metronomic chemotherapy.

Cecconetto L, Casadei Gardini A, Tenti E, Maltoni R, Bravaccini S, Oboldi D, Zoli W, Serra P, Donati C, Sarti S, Amadori D, Rocca A.

Tumori. 2014 May-Jun;100(3):e79-82. doi: 10.1700/1578.17238.

PMID:
25076256
17.

Copy number analysis of 24 oncogenes: MDM4 identified as a putative marker for low recurrence risk in non muscle invasive bladder cancer.

Salvi S, Calistri D, Gurioli G, Carretta E, Serra L, Gunelli R, Zoli W, Casadio V.

Int J Mol Sci. 2014 Jul 14;15(7):12458-68. doi: 10.3390/ijms150712458.

18.

First evidence of a large CHEK2 duplication involved in cancer predisposition in an Italian family with hereditary breast cancer.

Tedaldi G, Danesi R, Zampiga V, Tebaldi M, Bedei L, Zoli W, Amadori D, Falcini F, Calistri D.

BMC Cancer. 2014 Jul 1;14:478. doi: 10.1186/1471-2407-14-478.

19.

CSF-1 blockade impairs breast cancer osteoclastogenic potential in co-culture systems.

Liverani C, Mercatali L, Spadazzi C, La Manna F, De Vita A, Riva N, Calpona S, Ricci M, Bongiovanni A, Gunelli E, Zanoni M, Fabbri F, Zoli W, Amadori D, Ibrahim T.

Bone. 2014 Sep;66:214-22. doi: 10.1016/j.bone.2014.06.017. Epub 2014 Jun 20.

PMID:
24956020
20.

miRNAs as non-invasive biomarkers for lung cancer diagnosis.

Ulivi P, Zoli W.

Molecules. 2014 Jun 17;19(6):8220-37. doi: 10.3390/molecules19068220. Review.

21.

Assessment of DNA damage and telomerase activity in exfoliated urinary cells as sensitive and noninvasive biomarkers for early diagnosis of bladder cancer in ex-workers of a rubber tyres industry.

Cavallo D, Casadio V, Bravaccini S, Iavicoli S, Pira E, Romano C, Fresegna AM, Maiello R, Ciervo A, Buresti G, Zoli W, Calistri D.

Biomed Res Int. 2014;2014:370907. doi: 10.1155/2014/370907. Epub 2014 Apr 30.

22.

Target therapy in NSCLC patients: Relevant clinical agents and tumour molecular characterisation.

Ulivi P, Zoli W, Capelli L, Chiadini E, Calistri D, Amadori D.

Mol Clin Oncol. 2013 Jul;1(4):575-581. Epub 2013 Mar 29. Review.

23.

KRAS, BRAF and PIK3CA status in squamous cell anal carcinoma (SCAC).

Casadei Gardini A, Capelli L, Ulivi P, Giannini M, Freier E, Tamberi S, Scarpi E, Passardi A, Zoli W, Ragazzini A, Amadori D, Frassineti GL.

PLoS One. 2014 Mar 18;9(3):e92071. doi: 10.1371/journal.pone.0092071. eCollection 2014.

24.

Efficacy of different sequences of radio- and chemotherapy in experimental models of human melanoma.

Arienti C, Zoli W, Pignatta S, Carloni S, Paganelli G, Ulivi P, Romeo A, Menghi E, Sarnelli A, Medri L, Polico R, Silvestrini R, Tesei A.

J Cell Physiol. 2014 Oct;229(10):1548-56. doi: 10.1002/jcp.24598.

PMID:
24591063
25.

Circulating and stool nucleic acid analysis for colorectal cancer diagnosis.

De Maio G, Rengucci C, Zoli W, Calistri D.

World J Gastroenterol. 2014 Jan 28;20(4):957-67. doi: 10.3748/wjg.v20.i4.957. Review.

26.

Prolonged exposure to (R)-bicalutamide generates a LNCaP subclone with alteration of mitochondrial genome.

Pignatta S, Arienti C, Zoli W, Di Donato M, Castoria G, Gabucci E, Casadio V, Falconi M, De Giorgi U, Silvestrini R, Tesei A.

Mol Cell Endocrinol. 2014 Jan 25;382(1):314-324. doi: 10.1016/j.mce.2013.10.022. Epub 2013 Oct 25.

PMID:
24397920
27.

MMP-7 and fcDNA serum levels in early NSCLC and idiopathic interstitial pneumonia: preliminary study.

Ulivi P, Casoni GL, Foschi G, Scarpi E, Tomassetti S, Romagnoli M, Ravaglia C, Mengozzi M, Zoli W, Poletti V.

Int J Mol Sci. 2013 Dec 11;14(12):24097-112. doi: 10.3390/ijms141224097.

28.

DNA Methylation profiles as predictors of recurrence in non muscle invasive bladder cancer: an MS-MLPA approach.

Casadio V, Molinari C, Calistri D, Tebaldi M, Gunelli R, Serra L, Falcini F, Zingaretti C, Silvestrini R, Amadori D, Zoli W.

J Exp Clin Cancer Res. 2013 Nov 19;32:94. doi: 10.1186/1756-9966-32-94.

29.

In vitro irradiation system for radiobiological experiments.

Tesei A, Sarnelli A, Arienti C, Menghi E, Medri L, Gabucci E, Pignatta S, Falconi M, Silvestrini R, Zoli W, D'Errico V, Romeo A, Parisi E, Polico R.

Radiat Oncol. 2013 Nov 1;8:257. doi: 10.1186/1748-717X-8-257.

30.

Biofunctional characteristics of in situ and invasive breast carcinoma.

Bravaccini S, Granato AM, Medri L, Foca F, Falcini F, Zoli W, Ricci M, Lanzanova G, Masalu N, Serra L, Buggi F, Folli S, Silvestrini R, Amadori D.

Cell Oncol (Dordr). 2013 Jul;36(4):303-10. doi: 10.1007/s13402-013-0135-7. Epub 2013 Jun 27.

PMID:
23807750
31.

RANK/RANK-L/OPG in patients with bone metastases treated with anticancer agents and zoledronic acid: a prospective study.

Mercatali L, Ricci M, Scarpi E, Serra P, Fabbri F, Ricci R, Liverani C, Zanoni M, Zoli W, Maltoni R, Gunelli E, Amadori D, Ibrahim T.

Int J Mol Sci. 2013 May 23;14(6):10683-93. doi: 10.3390/ijms140610683.

32.

Gene methylation in rectal cancer: predictive marker of response to chemoradiotherapy?

Molinari C, Casadio V, Foca F, Zingaretti C, Giannini M, Avanzolini A, Lucci E, Saragoni L, Passardi A, Amadori D, Calistri D, Zoli W.

J Cell Physiol. 2013 Dec;228(12):2343-9. doi: 10.1002/jcp.24405.

PMID:
23702823
33.

Peripheral blood miR-328 expression as a potential biomarker for the early diagnosis of NSCLC.

Ulivi P, Foschi G, Mengozzi M, Scarpi E, Silvestrini R, Amadori D, Zoli W.

Int J Mol Sci. 2013 May 16;14(5):10332-42. doi: 10.3390/ijms140510332.

34.

Effect of small molecules modulating androgen receptor (SARMs) in human prostate cancer models.

Tesei A, Leonetti C, Di Donato M, Gabucci E, Porru M, Varchi G, Guerrini A, Amadori D, Arienti C, Pignatta S, Paganelli G, Caraglia M, Castoria G, Zoli W.

PLoS One. 2013 May 8;8(5):e62657. doi: 10.1371/journal.pone.0062657. Print 2013.

35.

Molecular determinations of EGFR and EML4-ALK on a single slide of NSCLC tissue.

Ulivi P, Puccetti M, Capelli L, Chiadini E, Bravaccini S, Calistri D, Zoli W, Amadori D, Candoli P.

J Clin Pathol. 2013 Aug;66(8):708-10. doi: 10.1136/jclinpath-2013-201502. Epub 2013 Mar 26.

PMID:
23533259
36.

Urine cell-free DNA integrity as a marker for early prostate cancer diagnosis: a pilot study.

Casadio V, Calistri D, Salvi S, Gunelli R, Carretta E, Amadori D, Silvestrini R, Zoli W.

Biomed Res Int. 2013;2013:270457. doi: 10.1155/2013/270457. Epub 2013 Feb 13.

37.

Multiple marker detection in peripheral blood for NSCLC diagnosis.

Ulivi P, Mercatali L, Casoni GL, Scarpi E, Bucchi L, Silvestrini R, Sanna S, Monteverde M, Amadori D, Poletti V, Zoli W.

PLoS One. 2013;8(2):e57401. doi: 10.1371/journal.pone.0057401. Epub 2013 Feb 26.

38.

Detection and recovery of circulating colon cancer cells using a dielectrophoresis-based device: KRAS mutation status in pure CTCs.

Fabbri F, Carloni S, Zoli W, Ulivi P, Gallerani G, Fici P, Chiadini E, Passardi A, Frassineti GL, Ragazzini A, Amadori D.

Cancer Lett. 2013 Jul 10;335(1):225-31. doi: 10.1016/j.canlet.2013.02.015. Epub 2013 Feb 16.

PMID:
23419522
39.

Cisplatin in combination with zoledronic acid: a synergistic effect in triple-negative breast cancer cell lines.

Ibrahim T, Liverani C, Mercatali L, Sacanna E, Zanoni M, Fabbri F, Zoli W, Amadori D.

Int J Oncol. 2013 Apr;42(4):1263-70. doi: 10.3892/ijo.2013.1809. Epub 2013 Feb 6. Erratum in: Int J Oncol. 2016 Sep;49(3):1260.

PMID:
23403907
40.

Specific Biomarkers Are Associated with Docetaxeland Gemcitabine-Resistant NSCLC Cell Lines.

Pasini A, Paganelli G, Tesei A, Zoli W, Giordano E, Calistri D.

Transl Oncol. 2012 Dec;5(6):461-8. Epub 2012 Dec 1.

41.

Phase II trial of non-pegylated liposomal doxorubicin and low-dose prednisone in second-line chemotherapy for hormone-refractory prostate cancer.

Montanari M, Fabbri F, Rondini E, Frassineti GL, Mattioli R, Carloni S, Scarpi E, Zoli W, Amadori D, Cruciani G.

Tumori. 2012 Nov;98(6):696-701. doi: 10.1700/1217.13491.

PMID:
23389354
42.

Role of conventional chemosensitivity test and tissue biomarker expression in predicting response to treatment of peritoneal carcinomatosis from colon cancer.

Arienti C, Tesei A, Verdecchia GM, Framarini M, Virzì S, Grassi A, Scarpi E, Turci L, Silvestrini R, Amadori D, Zoli W.

Clin Colorectal Cancer. 2013 Jun;12(2):122-7. doi: 10.1016/j.clcc.2012.11.006. Epub 2013 Jan 16.

PMID:
23332421
43.

SLUG silencing increases radiosensitivity of melanoma cells in vitro.

Arienti C, Tesei A, Carloni S, Ulivi P, Romeo A, Ghigi G, Menghi E, Sarnelli A, Parisi E, Silvestrini R, Zoli W.

Cell Oncol (Dordr). 2013 Apr;36(2):131-9. doi: 10.1007/s13402-012-0120-6. Epub 2012 Dec 19.

PMID:
23250725
44.

Inhibition of breast cancer cell proliferation in repeated and non-repeated treatment with zoledronic acid.

Ibrahim T, Mercatali L, Sacanna E, Tesei A, Carloni S, Ulivi P, Liverani C, Fabbri F, Zanoni M, Zoli W, Amadori D.

Cancer Cell Int. 2012 Nov 22;12(1):48. doi: 10.1186/1475-2867-12-48.

45.

Urine cell-free DNA integrity as a marker for early bladder cancer diagnosis: preliminary data.

Casadio V, Calistri D, Tebaldi M, Bravaccini S, Gunelli R, Martorana G, Bertaccini A, Serra L, Scarpi E, Amadori D, Silvestrini R, Zoli W.

Urol Oncol. 2013 Nov;31(8):1744-50. doi: 10.1016/j.urolonc.2012.07.013. Epub 2012 Nov 7.

PMID:
23141783
46.

Extended depth of focus in optical microscopy: assessment of existing methods and a new proposal.

Piccinini F, Tesei A, Zoli W, Bevilacqua A.

Microsc Res Tech. 2012 Nov;75(11):1582-92. doi: 10.1002/jemt.22104. Epub 2012 Sep 13.

PMID:
22972756
47.

Perspectives on mTOR inhibitors for castration-refractory prostate cancer.

Burgio SL, Fabbri F, Seymour IJ, Zoli W, Amadori D, De Giorgi U.

Curr Cancer Drug Targets. 2012 Oct;12(8):940-9. Review.

PMID:
22831278
48.

EGFR and K-ras mutations in cytologic samples from fine-needle aspirates in NSCLC patients.

Ulivi P, Zoli W, Chiadini E, Capelli L, Candoli P, Calistri D, Silvestrini R, Puccetti M.

Eur Respir J. 2012 Jul;40(1):267-9. doi: 10.1183/09031936.00204511. No abstract available.

49.

Urinary biomarkers of non-muscle-invasive bladder cancer: current status and future potential.

Calistri D, Casadio V, Bravaccini S, Zoli W, Amadori D.

Expert Rev Anticancer Ther. 2012 Jun;12(6):743-52. doi: 10.1586/era.12.50.

PMID:
22716491
50.

Predictive role of telomerase activity in the clinical outcome of patients with benign lesions of the uterine cervix or CIN.

Bravaccini S, Amadori A, Scarpi E, Tumedei MM, Zoli W, Silvestrini R.

Anal Cell Pathol (Amst). 2012;35(5-6):377-80. doi: 10.3233/ACP-2012-0066.

Supplemental Content

Support Center